E
KLDO

Ergoteles’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Ergoteles’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-19,600
Closed -$47K – 1773
2021
Q4 		$47K Buy
+19,600
New +$79.8K ﹤0.01% 1182

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ergoteles's KLDO Position: Q1 2022 in Review

Ergoteles sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q1 2022, closing a stake of 19,600 shares — an estimated $47K sold.

Ergoteles first reported a position in KLDO in Q4 2021 and held it in 1 quarter. The position peaked at $47K in Q4 2021. 63 funds tracked by Wall St. Rank hold KLDO as of Q1 2022.

  • Ergoteles reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Ergoteles sold 19,600 Kaleido Biosciences, Inc. Common Stock shares in Q1 2022, an estimated $47K.
  • Ergoteles first reported a position in Kaleido Biosciences, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Ergoteles's Kaleido Biosciences, Inc. Common Stock position peaked at $47K in Q4 2021.
  • 63 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q1 2022.

Based on Ergoteles's 13F filing for Q1 2022, filed 13 May 2022.